Soligenix Inc. (SNGX) Stock on the Rise Following Key Milestone in Development of CiVax

Soligenix Inc. (SNGX) stock prices were up by 3.03% shortly after market trading commenced on October 8th, 2021. This brought the price per share up to USD$1.02 early on in the trading day.

CiVax Developmental Milestone

October 7th 2021 saw SNGX stock announce hitting another key milestone earlier in the weak with its heat-stable vaccine program, CiVax. This is a substantial development since shipping and administered existing Covid-19 vaccines have to be stored at sub-zero temperatures. This fact has been challenging global efforts at recovery from the pandemic. The company announced on September 28th, 2021 the positive efficacy test results for CiVax on non-human primates. The treatment demonstrated durable broad-spectrum neutralizing antibody responses against the Covid-19 virus and several of its emerging variants

SNGX Stock’s Ongoing Global Efforts

The immunogenicity study is pre-clinical, with various steps still left before CiVax can be implemented as a global vaccine option. the proof of concept, however, has indicated the potential to help accelerate recovery effort around the world. Existing vaccines have been slowing the spread, but variant infections are outpacing ongoing vaccination efforts. SNGX stock is delivering on the expert opinion that suggests the Covid-19 pandemic may still have some ways to go.

Network of Treatments

The company’s heat stabilization technology, ThermoVax, has also shown promising results with other protein subunit vaccines. The monovalent, bivalent, and trivalent formulations are the most advanced so far. These target filovirus infections, including Zaire and Sudan ebolavirus, and Marburg is important to consider other threats concurrent and subsequent to the ongoing worldwide coronavirus pandemic. Filoviruses are not as widespread as the Covid-19 strain the world is facing, but they are still highly lethal and considered a major threat by the world’s medical community.

SNGX Stock Targets Additional Viruses

There is only one existing vaccine for Zaire ebolavirus that has been approved by the United States Food and Drug Administration. The existing treatment option is not heat-stabilized and needs to be shipping and stored at temperatures of negative 75 Fahrenheit. The logistics required to maintain this are highly difficult in more remote areas.

Future Outlook for SNGX Stock

SNGX stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of its latest CiVax development. The company is keen to expand its market footprint in a burgeoning sector as the world hurtles towards universal immunizations. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal.